Antimicrobial resistance continues to be a public threat on a global scale. The ongoing need
to develop new antimicrobial drugs that are effective against multi-drug-resistant pathogens …

Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …

Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of
people worldwide. However recent studies have indicated that niclosamide may have broad …

The rapid development of new anticancer drugs that are safe and effective is a common goal
shared by basic scientists, clinicians and patients. The current review discusses one such …

Purpose: Enzalutamide, a second-generation antiandrogen, was recently approved for the
treatment of castration-resistant prostate cancer (CRPC) in patients who no longer respond …

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that
are already known for use treating other diseases. The advantages of this are that several …

Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has
been demonstrated in 22%~ 65% of non-small cell lung cancers (NSCLC). STAT3 activation …

Drug repositioning may be defined as a process when new biological effects for known
drugs are identified, leading to recommendations for new therapeutic applications …

Niclosamide is an anthelmintic drug that has been used for over 50 years mainly to treat
tapeworm infections. However, with the increase in drug repurposing initiatives, niclosamide …

The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a
promising anticancer target. We identified a small-molecule Bcl2-BH4 domain antagonist …